Our portfolio spans pharmaceuticals, platforms, devices, and diagnostics — from pre-seed through seed stage, with a focus on companies that enhance human potential.
Novel small-molecule program targeting a validated genetic pathway in rare disease, currently advancing through preclinical development.
AI-driven platform for computational drug discovery, applying machine learning to accelerate target identification and lead optimization.
Next-generation molecular diagnostics platform enabling early detection through proprietary biomarker analysis.